CVR 26524938Public limited company (A/S)Fremstilling af farmaceutiske præparater (212000)Englandsvej 350, 2770 KastrupFounded 27 Feb 2002
Compare withsimilar companiesanother companyits industry
PHARMADAN A/S
CVR holds no employment figures for this company.
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: PHARMADAN A/S, https://dandex.ai/company/26524938/pharmadan. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about PHARMADAN A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexGross profit
-6.4M
DKK, annual report 2025
Result
-5.4M
DKK, annual report 2025
Equity
-19M
DKK, annual report 2025
H&P Rørvig Holding A/SCVR 27510434, 100% of capital and votes
Peter Rørvigsince 31 May 2006
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 27510434100% of capital and votessince 19 Nov 2013
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -6.4M, Operating profit -6.5M, Result for the year -5.4M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 2.2M, Equity -19M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -2,844 | -3,128 | -4,923 | -5,841 | -6,383 |
| Operating profit | -3,158 | -3,440 | -5,215 | -6,074 | -6,469 |
| Result for the year | -2,511 | -2,753 | -4,168 | -5,114 | -5,427 |
| Equity | -1,494 | -4,247 | -8,415 | -13,528 | -18,955 |
| Total assets | 3,113 | 2,683 | 4,518 | 6,822 | 2,217 |
| Employees (average) | Not reported | Not reported | Not reported | Not reported | 0 |
Annual report 2025
1 Jul 2024 to 30 Jun 2025, published 15 Dec 2025
Annual report 2024
1 Jul 2023 to 30 Jun 2024, published 12 Dec 2024
Annual report 2023
1 Jul 2022 to 30 Jun 2023, published 21 Dec 2023
Annual report 2022
1 Jul 2021 to 30 Jun 2022, published 5 Dec 2022
Annual report 2021
1 Jul 2020 to 30 Jun 2021, published 7 Dec 2021
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseDebt conversionPaid in 8,000,000 | None | 8,000,000 | None | 600,000 | |
| IncreaseDebt conversionPaid in 7,000,000 | None | 7,000,000 | None | 550,000 | |
| FoundingNot read from the announcement | None | None | None | 500,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| EBITDA | -2,844 | -3,128 | -4,923 | -5,841 | -6,383 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 0note 1 | 107note 2 | 0note 1 | 2note 2 | 0note 1 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 22 Nov 2026.
13 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 62550511 BIOFAC A/S (fortsættende) og CVR-nummer: 26524938 PHARMADAN A/S (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 62550511 BIOFAC A/S og CVR-nummer: 26524938 PHARMADAN A/S må antages at være tilstrækkeligt sikrede efter fusionen.
Vedtægter ændret: 20.04.2023
Selskabet tegnes af en direktør eller af et bestyrelsesmedlem.
Bestyrelse:
Fratrådte:
Svend Blankholm, den 13.02.2020.
Vedtægter ændret: 08.12.2015
Kapitalforhøjelse: kr. 50.000,00, indbetalt ved konvertering af gæld, kurs 16.000,00.
Kapitalen udgør herefter kr. 600.000,00.
Vedtægter ændret:
19.11.2013.
Kapitalforhøjelse:
kr. 50.000,00 indbetalt ved konvertering af gæld, kurs 14.000,00.
Kapitalen udgør herefter kr. 550.000,00.
Vedtægter ændret:
16.10.2006.
Selskabet tegnes af en direktør eller af to bestyrelsesmedlemmer i forening.
Direktion:
Udtrådt af direktionen:
Niels Otto Thiesen, den 31.05.2006.
Indtrådt i direktionen:
Direktør Peter Rørvig, den 31.05.2006.
Stiftelsesdato:
27.02.2002.
Seneste vedtægtsdato:
27.02.2002.
Kapital:
kr. 500.000,00.
Indbetalingsmåde:
kontant kr. 500.000,00 til kurs 100,00.
Stifter:
CVR-NR. 12335040 DANIPHARM A/S, Englandsvej 350-356, 2770 Kastrup, den 27.02.2002.
Bestyrelse:
Advokat Niels Ulrik Heine, den 27.02.2002, Direktør Peter Rørvig, den 27.02.2002, Direktør Niels Otto Thiesen, den 27.02.2002.
Direktion:
Direktør Niels Otto Thiesen, den 27.02.2002.
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening eller af to bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 16994294 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, Strandvejen 44, 2900 Hellerup, den 27.02.2002.
Første regnskabsår:
27.02.2002 - 30.06.2002.
Regnskabsår:
01.07 - 30.06.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for PHARMADAN A/S:
Have Pro? Sign in.
P-number 1009012253Sognevejen 92, 9620 Aalestrup